Supreme Court To Hear MedImmune Patent Case Against Genentech
This article was originally published in The Pink Sheet Daily
Executive Summary
MedImmune’s suit challenges the validity of the Cabilly patent, which it licenses from Genentech.
You may also be interested in...
Declaratory Judgment Ruling From U.S. Supreme Court Could Impact Licensing Deals, ANDAs
High court is mulling MedImmune's right to challenge a patent licensed from Genentech while continuing to make royalty payments.
Declaratory Judgment Ruling From U.S. Supreme Court Could Impact Licensing Deals, ANDAs
High court is mulling MedImmune's right to challenge a patent licensed from Genentech while continuing to make royalty payments.
MedImmune Plans To Expand Sales Force As It Reacquires Synagis Promotion Rights
Abbott will release co-promotion rights for the respiratory syncytial virus therapy effective June 30, 2006.